期刊文献+

赛尼哌对肾移植急性排斥反应的预防作用 被引量:2

暂未订购
导出
摘要 目的 :观察赛尼哌对肾移植急性排斥反应 (AR)的预防作用及其安全性评估。方法 :选择同期肾移植病人 5 0例 ,分为治疗和对照两组 ,各 2 5例。治疗组术前静滴赛尼哌 2 5mg ,同时口服骁悉 (MMF) 0 75g ,对照组仅口服MMF 0 75g ;术后两组病人均予甲基强的松龙冲击 ,常规强的松 (Pred)、环孢素 (CsA)和MMF三联抗排斥治疗。结果 :治疗组 3例发生AR ,对照组 9例 ,相差显著 (P <0 0 1) ;治疗组AR经强化治疗均逆转 ,对照组 7例逆转 ,另 2例失败 ;感染、胃肠道反应及血液系统损害两组差异无显著意义 (P >0 0 5 )。结论 :赛尼哌可显著降低AR发生率 ,且安全性好。
出处 《实用医学杂志》 CAS 2001年第12期1209-1210,共2页 The Journal of Practical Medicine
  • 相关文献

参考文献3

  • 1[1]Ek Berg H,Backman L,Tufveson G,et al. Daclizumab prevents acute rejection and improves patient survival post transplantation:l year pooled analysis. Transplant Int,2000,13(2):151~159.
  • 2[2]Meier K,Herwig U,Kaza F,et al. The effect of daclizumab in a High-risk renal transplant population. Chin Transplant,2000,14(5):509~513.
  • 3[3]Chang X,George J,Mahanty K,et al. A calcineurin inhibitor-sparing regimen with sirolimus,mycophenolate mofetil,and anti-CD25 mAb provides effective immunosuppression in kidney transplant recipients with delayed or impaired graft function. Clin Transplant,2000,14(6):550~554.

同被引文献16

  • 1WekerleT 朱瑾.混合性嵌合体作为移植耐受诱导物以探讨临床复合移植的潜在可能性[J].创伤骨科论坛,2000,29(3):268-270.
  • 2Vincenti F. Daclizumb: novel biologic immunoprophylaxis for prevention of acute rejection inrenal Transplant Proc, 1999, 31 : 2206 - 2207.
  • 3Goebd J, Stevens E, Forrest K, et al. Daclizumab (Zenapax) inhibits early interleukin - 2 receptor signal transduction events.Transplant Immunol, 2000, 8: 153-159.
  • 4Vincenti F, Kitkman R, Eight S, et al. Interleukin - 2 - receptor block-ade with daclizunmb to prevent acute rejection in renal transplantation N Engl J Med, 1998, 338: 161.
  • 5Starzl TE,Demetris A J,Murasen,et al.Cell migration,chimerism,and graft acceptancet [J].Lancet 1992,339:1579-1582
  • 6Lo YMD,Tein MSC,Pang CCP,et al.Presence of donor specific DNA in plasma of kidney and liver transplant recipients[Letter] [J].Lancet,1998,351:1329-1330
  • 7Zhang J,Tong KL,Li PK,et al.Presence of doner and recipient-derived DNA in cell-free urine samles of renal transplantion recipients:urinary DNA chimerism [J].Clinical chemistry,1999,45(10):1741-1746
  • 8Mchaniel D,Naftilan J,Hulvey K,et al.Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow [J].Transplantation,1994,57:852
  • 9NierhoffD,Horvath HC,Mytilineos J,et al.Microchimerism in bone marrow-derived CD34^+ cells of patients after liver transplantation Blood [J].2000,96(2):763-767
  • 10Shirwan H,Wu GD,Barwrt L,et al.Induction of allograft nonresponsiveness after intrathymic inoculation with donor class Ⅰ allopeptides:Ⅱ .Evidence for persistent chronic rejection depite high levels of donor microchimerism [J].Transplantation,1997,64:1671-1676

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部